New epilepsy drug candidate enters first human safety tests

NCT ID NCT07156201

Recruiting now Knowledge-focused Sponsor: Actio Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug called ABS-1230 in 74 healthy adults to see if it is safe and how the body processes it. The drug is being developed for a rare type of epilepsy caused by changes in the KCNT1 gene. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABS-1230
What this could lead to: If this trial shows ABS-1230 is safe, it could pave the way for testing it as a treatment for KCNT1-related epilepsy.
What could go wrong: This is a very early, small study in healthy people, not patients. It only looks at safety and how the drug moves through the body, not whether it works for epilepsy. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates